Table 4.

Characteristics of published completed trials

Ref	Country	Year of publication	Steroid used	Primary outcomes	P value
[24]	China	2020	Methylprednisolone 396 of 409 [96.8%], dexamethasone 32 of 409 [7.8%] patients—hydrocortisone equivalent	Corticosteroid therapy had higher 28-day mortality rate. Delay in SARS-CoV RNA clearance (P = 0.00017)	< 0.05
[25]	USA	2020	Hydrocortisone 200 mg/day and tapered till 50 mg/day	Treatment failure occurred in hydrocortisone patient is 42.1% compared to placebo 50.7%	< 0.045
[26]	Netherlands	2020	Methylprednisolone 80 mg, 250 mg	There was a 79% higher likelihood of two stage improvement in respiratory status	< 0.025
[27]	USA	2020	Hydrocortisone 50 mg, 100 mg	The in-hospital death in treatment group is 30% and 26% compared to no hydrocortisone, i.e. 33%	< 0.05